Influenza: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(→‎Epidemiology: Organized)
mNo edit summary
 
(32 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{subpages}}  
{{subpages}}  
{{TOC-right}}
{{TOC|right}}
'''Influenza''', commonly called “the ‘Flu”, is described as "an acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the nasal mucosa; the pharynx; and conjunctiva, and by headache and severe, often generalized, myalgia".<ref name="pmid">{{cite journal |author=National Library of Medicine |title=Influenza |journal= |volume= |issue= |pages= |year= |pmid= |doi= |issn=}}</ref> It is contagious (easily passed from one person to another) and is caused by viruses of the [[Orthomyxoviridae]] family.


'''Influenza''', commonly called “the ‘Flu”, is described as "an acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the nasal mucosa; the pharynx; and conjunctiva, and by headache and severe, often generalized, myalgia".<ref name="pmid">{{cite journal |author=National Library of Medicine |title=Influenza |journal= |volume= |issue= |pages= |year= |pmid= |doi= |issn=}}</ref> It is contagious (easily passed from one person to another) and is caused by viruses of the [[Orthomyxoviridae]] family.
==Classification==
There are three types of influenza viruses:<ref name="CDC-flu/avian/gen-info/flu-viruses.htm Influenza">Anonymous (2005)[http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm Influenza Viruses], [[Centers for Disease Control and Prevention]]</ref>
* [[Influenza A virus]]. "Influenza A viruses are further classified by subtype on the basis of the two main surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Influenza A subtypes and B viruses are further classified by strains."<ref name="CDC-flu/avian/gen-info/flu-viruses.htm Influenza"/>
** [[2009 H1N1 influenza virus]]
* [[Influenza B virus]]
* [[Influenza C virus]]


''This article is focused on the disease. For details of the causative viruses:''
{{seealso|Influenza A virus}}
{{seealso|2009 H1N1 influenza virus}}
{{seealso|Influenza B virus}}
==Hosts==
==Hosts==
===Influenza in humans===
===Influenza in humans===
Symptoms of Influenza include headache, coughing and other cold-like symptoms.   These are accompanied by a high fever. The flu is easily treated with modern medicines, but many strains are nevertheless quite serious, particularly for children and older persons.
In April, 2009, the [[2009 H1N1 influenza virus]] was first isolated and is a ''novel H1N1'' strain that was initially untypeable. The 2009 novel H1N1 influenza virus contains genes normally found in North American swine as well as two genes found in European and Asian swine and has been called a triple-reassortant of genes.<ref name="pmid19423869">{{cite journal| author=Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S et al.| title=Emergence of a novel swine-origin influenza A (H1N1) virus in humans. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 25 | pages= 2605-15 | pmid=19423869
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19423869 | doi=10.1056/NEJMoa0903810 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref>[http://www.cdc.gov/h1n1flu/swineflu_you.htm Swine Flu & You]</ref>
 
In the 2007-2008 season, the most common strains of influenza in the United States were:<ref>[http://www.cdc.gov/flu/weekly/weeklyarchives2007-2008/07-08summary.htm 2007-08 U.S. INFLUENZA SEASON SUMMARY], Centers for Disease Control and Prevention</ref>
* [[influenza A virus]] (H1N1) 35%
* [[influenza A virus]] (H3N2) 35%
* [[influenza B virus]] 30%
 
In the 1999-2000 season, the most common strains of influenza in the United States were:<ref>[http://www.cdc.gov/ncidod/diseases/flu/WeeklyArchives1999-2000/99-00summary2.htm 1999-2000 INFLUENZA SEASON SUMMARY], Centers for Disease Control and Prevention</ref>
* [[influenza A virus]] (H1N1) 3%
* [[influenza A virus]] (H3N2) 99%
* [[influenza B virus]] 0.6%


===Equine Influenza===
===Equine Influenza===
Line 21: Line 34:


==Epidemiology==
==Epidemiology==
[[Image:Labsummary06-07.GIF|right|thumb|250px|{{#ifexist:Template:Labsummary06-07.GIF/credit|{{Labsummary06-07.GIF/credit}}<br/>|}}Seasonal influenza activity in the [[United States]] over four years. During the off season, the prevalence is < 2%. During the height of season, the prevalence may be 20-35%.<ref name="titleCDC - Influenza (Flu) | Flu Activity">{{cite web |url=http://www.cdc.gov/flu/weekly/fluactivity.htm |title=Flu Activity |accessdate=2007-11-29 |author=Centers for Disease Control and Prevention |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>]]
[[Image:Labsummary06-07.GIF|right|thumb|250px|{{#ifexist:Template:Labsummary06-07.GIF/credit|{{Labsummary06-07.GIF/credit}}<br/>|}}Seasonal influenza activity in the [[United States of America]] over four years. During the off season, the prevalence is < 2%. During the height of season, the prevalence may be 20-35%.<ref name="titleCDC - Influenza (Flu) | Flu Activity">{{cite web |url=http://www.cdc.gov/flu/weekly/fluactivity.htm |title=Flu Activity |accessdate=2007-11-29 |author=Centers for Disease Control and Prevention |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref>]]


Current influenza activity can be monitored online:
Current influenza activity can be monitored online:
* In the [[United States]], the [[Centers for Disease Control and Prevention]] (CDC) maintains public statistics at http://www.cdc.gov/flu/weekly/fluactivity.htm.]]
* In the [[United States of America]], the [[Centers for Disease Control and Prevention]] (CDC) maintains public statistics at http://www.cdc.gov/flu/weekly/fluactivitysurv.htm.
* Google maintains statistics based on search terms (http://www.google.org/flutrends/).<ref name="urlGoogle Uses Web Searches to Track Flu’s Spread - NYTimes.com">{{cite web |url=http://www.nytimes.com/2008/11/12/technology/internet/12flu.html |title=Google Uses Web Searches to Track Flu’s Spread - NYTimes.com |author=Helft M |authorlink= |coauthors= |date=Nov 11, 2008 |format= |work= |publisher=New York Times Company |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2008-11-11}}</ref>
* Google maintains statistics based on search terms (http://www.google.org/flutrends/).<ref name="urlGoogle Uses Web Searches to Track Flu’s Spread - NYTimes.com">{{cite web |url=http://www.nytimes.com/2008/11/12/technology/internet/12flu.html |title=Google Uses Web Searches to Track Flu’s Spread - NYTimes.com |author=Helft M |authorlink= |coauthors= |date=Nov 11, 2008 |format= |work= |publisher=New York Times Company |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2008-11-11}}</ref>
* http://healthmap.org/
* http://healthmap.org/


The prevalence of influenza among people who have an "influenza-like illness" varies strongly with the seasons of the year. In the [[United States]], the [[Centers for Disease Control and Prevention]] (CDC) maintains public statistics at http://www.cdc.gov/flu/weekly/fluactivity.htm.
The prevalence of influenza among people who have an "influenza-like illness" varies strongly with the seasons of the year. In the [[United States of America]], the [[Centers for Disease Control and Prevention]] (CDC) maintains public statistics at http://www.cdc.gov/flu/weekly/fluactivity.htm.
* During the off season, the  the prevalence is < 2%<ref name="titleCDC - Influenza (Flu) | Flu Activity"/>
* During the off season, the prevalence is < 2%<ref name="titleCDC - Influenza (Flu) | Flu Activity"/>
* During the height of season, the prevalence may be 20-35%.<ref name="titleCDC - Influenza (Flu) | Flu Activity"/>
* During the height of season, the prevalence may be 20-35%.<ref name="titleCDC - Influenza (Flu) | Flu Activity"/>
* During local outbreaks, the prevalence may be 50-80% according to studies.<ref name="pmid12361816">{{cite journal | author = Smith K, Roberts M | title = Cost-effectiveness of newer treatment strategies for influenza. | journal = Am J Med | volume = 113 | issue = 4 | pages = 300-7 | year = 2002 | doi = 10.1016/S0002-9343(02)01222-6 | id = PMID 12361816}}</ref><ref name="pimd12965940">{{cite journal | author = Rothberg M, Bellantonio S, Rose D | title = Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. | journal = Ann Intern Med | volume = 139 | issue = 5 Pt 1 | pages = 321-9 | year = 2003 | url = http://www.annals.org/cgi/content/abstract/139/5_Part_1/321 | id = PMID 12965940}}</ref> Unfortunately, the CDC does not report sufficient details to determine where local outbreaks are occurring.
* During local outbreaks, the prevalence may be 50-80% according to studies.<ref name="pmid12361816">{{cite journal | author = Smith K, Roberts M | title = Cost-effectiveness of newer treatment strategies for influenza. | journal = Am J Med | volume = 113 | issue = 4 | pages = 300-7 | year = 2002 | doi = 10.1016/S0002-9343(02)01222-6 | id = PMID 12361816}}</ref><ref name="pimd12965940">{{cite journal | author = Rothberg M, Bellantonio S, Rose D | title = Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. | journal = Ann Intern Med | volume = 139 | issue = 5 Pt 1 | pages = 321-9 | year = 2003 | url = http://www.annals.org/cgi/content/abstract/139/5_Part_1/321 | id = PMID 12965940}}</ref> Unfortunately, the CDC does not report sufficient details to determine where local outbreaks are occurring.
Line 37: Line 50:
==Diagnosis==
==Diagnosis==
===History and physical examination===
===History and physical examination===
Since anti-viral drugs are effective in treating influenza if given early (see treatment section, below), it can be important to identify cases early. A [[systematic review]] by the [http://jama.ama-assn.org/cgi/collection/rational_clinical_exam Rational Clinical Examination] concluded that the best findings for excluding the diagnosis of influenza are:<ref name="pmid15728170">{{cite journal | author = Call S, Vollenweider M, Hornung C, Simel D, McKinney W | title = Does this patient have influenza? | journal = JAMA | volume = 293 | issue = 8 | pages = 987-97 | year = 2005 | doi = 10.1001/jama.293.8.987 | id = PMID 15728170}}</ref>
Since anti-viral drugs are effective in treating influenza if given early (see treatment section, below), it can be important to identify cases early. A [[systematic review]] by the [http://jama.ama-assn.org/cgi/collection/rational_clinical_exam Rational Clinical Examination] concluded that the best findings for excluding the diagnosis of influenza are:<ref name="pmid15728170">{{cite journal| author=Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP| title=Does this patient have influenza? | journal=JAMA | year= 2005 | volume= 293 | issue= 8 | pages= 987-97 | pmid=15728170
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15728170 | doi=10.1001/jama.293.8.987 }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16247902 Review in: Evid Based Nurs. 2005 Oct;8(4):121]</ref>


{| class="wikitable"
{| class="wikitable"
Line 48: Line 62:
! Cough†
! Cough†
| style="text-align:center"|98%† ||style="text-align:center"| 23%
| style="text-align:center"|98%† ||style="text-align:center"| 23%
|-
! Sore throat
| style="text-align:center"|~80%† ||style="text-align:center"| ~30%
|-
|-
! Nasal congestion†
! Nasal congestion†
Line 59: Line 76:
|}
|}


Using the symptoms listed above, the ''combinations'' of findings below can improve diagnostic accuracy.<ref name="pmid11088084">{{cite journal | author = Monto A, Gravenstein S, Elliott M, Colopy M, Schweinle J | title = Clinical signs and symptoms predicting influenza infection. | journal = Arch Intern Med | volume = 160 | issue = 21 | pages = 3243–7 | year = 2000 | url http://archinte.ama-assn.org/cgi/content/abstract/160/21/3243 | id = PMID 11088084}}</ref> Unfortunately, even combinations of findings are imperfect. However, [[Bayes Theorem]] can combine pretest probability with clinical findings to adequately diagnose or exclude influenza in some patients. The pretest probability has a strong seasonal variation; the current prevalence of influenza among patients in the United States receiving sentinel testing is available at the [[Centers for Disease Control and Prevention|CDC]].<ref>Centers for Disease Control and Prevention.  [http://www.cdc.gov/flu/weekly/ Weekly Report: Influenza Summary Update.] Accessed January 1, 2007.</ref>  Using the CDC data, the following table shows how the likelihood of influenza varies with prevalence:
Using the symptoms listed above, the ''combinations'' of findings below can improve diagnostic accuracy.<ref name="pmid11088084">{{cite journal | author = Monto A, Gravenstein S, Elliott M, Colopy M, Schweinle J | title = Clinical signs and symptoms predicting influenza infection. | journal = Arch Intern Med | volume = 160 | issue = 21 | pages = 3243–7 | year = 2000 | url http://archinte.ama-assn.org/cgi/content/abstract/160/21/3243 | id = PMID 11088084}}</ref> Unfortunately, even combinations of findings are imperfect. Studies of combining symptoms have included use of recursive partitioning; however, this study combined two cohorts with different prevalences of influenza.<ref name="pmid22427440">{{cite journal| author=Afonso AM, Ebell MH, Gonzales R, Stein J, Genton B, Senn N| title=The use of classification and regression trees to predict the likelihood of seasonal influenza. | journal=Fam Pract | year= 2012 | volume=  | issue=  | pages=  | pmid=22427440 | doi=10.1093/fampra/cms020 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22427440  }} </ref> However, [[Bayes Theorem]] can combine pretest probability with clinical findings to adequately diagnose or exclude influenza in some patients. The pretest probability has a strong seasonal variation; the current prevalence of influenza among patients in the United States receiving sentinel testing is available at the [[Centers for Disease Control and Prevention|CDC]].<ref>Centers for Disease Control and Prevention.  [http://www.cdc.gov/flu/weekly/ Weekly Report: Influenza Summary Update.] Accessed January 1, 2007.</ref>  Using the CDC data, the following table shows how the likelihood of influenza varies with prevalence:
:
:


<table border="1" cellpadding="5" class="wikitable">
<table border="1" cellpadding="5" class="wikitable">
<caption>Combinations of findings for diagnosing influenza<ref name="pmid15728170"/></caption>
<caption>Combinations of findings for diagnosing influenza<ref name="pmid22218625">{{cite journal| author=Ebell MH, Afonso AM, Gonzales R, Stein J, Genton B, Senn N| title=Development and validation of a clinical decision rule for the diagnosis of influenza. | journal=J Am Board Fam Med | year= 2012 | volume= 25 | issue= 1 | pages= 55-62 | pmid=22218625 | doi=10.3122/jabfm.2012.01.110161 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22218625  }} </ref><ref name="pmid15728170"/></caption>
   <tr>
   <tr>
     <th rowspan="2">Combinations of findings </th>
     <th rowspan="2">Combinations of findings </th>
Line 85: Line 102:
   <tr>
   <tr>
     <td>Fever and cough</td>
     <td>Fever and cough</td>
     <td align="center">64%</td>
     <td align="center">64%<br/>61%<ref name="pmid22218625"/></td>
     <td align="center">67%</td>
     <td align="center">67%<br/>80%<ref name="pmid22218625"/></td>
     <td align="center">79%</td>
     <td align="center">79%<br/>86%<ref name="pmid22218625"/></td>
     <td align="center">49%</td>
     <td align="center">49%<br/>49%<ref name="pmid22218625"/></td>
     <td align="center">39%</td>
     <td align="center">39%<br/>50%<ref name="pmid22218625"/></td>
     <td align="center">15%</td>
     <td align="center">15%<br/>14%<ref name="pmid22218625"/></td>
     <td align="center">4%</td>
     <td align="center">4%<br/>6%<ref name="pmid22218625"/></td>
     <td align="center">1%</td>
     <td align="center">1%<br/>1%<ref name="pmid22218625"/></td>
   </tr>
   </tr>
   <tr>
   <tr>
Line 114: Line 131:
     <td align="center">16</td>
     <td align="center">16</td>
     <td align="center">4</td>
     <td align="center">4</td>
    <td align="center">1</td>
  </tr>
<tr>
    <td>Fever and cough and acute onset<ref name="pmid22218625"/></td>
    <td align="center">41</td>
    <td align="center">93</td>
    <td align="center">92</td>
    <td align="center">55</td>
    <td align="center">66</td>
    <td align="center">18</td>
    <td align="center">11</td>
     <td align="center">1</td>
     <td align="center">1</td>
   </tr>
   </tr>
Line 119: Line 147:


===Laboratory tests===
===Laboratory tests===
Rapid tests include [[immunofluorescence]] assays, [[immunoenzyme technique]], and [[polymerase chain reaction]] testing. The [[sensitivity and specificity|sensitivity]] of these tests range from 63% to 95%.<ref>Beyer WE. Heterogeneity of case definitions used in vaccine effectiveness studies--and its impact on meta-analysis. Vaccine. 2006 Nov 10;24(44-46):6602-4. Epub 2006 Jun 8.
{{Image|Flu-virus2.jpg|right|350px|An electron tomography of the influenza virus.}}
Available tests are [http://www.cdc.gov/flu/professionals/diagnosis/labprocedures.htm listed at the CDC website].
 
[[Clinical practice guideline]]s address diagnosis.<ref name="pmid19281331">{{cite journal| author=Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG et al.| title=Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 8 | pages= 1003-32 | pmid=19281331
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19281331 | doi=10.1086/598513 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
 
Rapid tests using for influenza antigens include [[immunofluorescence]] assays, [[immunoenzyme technique]], and [[polymerase chain reaction]] testing. The [[sensitivity and specificity|sensitivity]] of these tests range from 63% to 95%.<ref>Beyer WE. Heterogeneity of case definitions used in vaccine effectiveness studies--and its impact on meta-analysis. Vaccine. 2006 Nov 10;24(44-46):6602-4. Epub 2006 Jun 8.
PMID 16797799</ref><ref>Rodriguez WJ, Schwartz RH, Thorne MM. Evaluation of diagnostic tests for influenza in a pediatric practice. Pediatr Infect Dis J. 2002 Mar;21(3):193-6. PMID 12005080</ref>
PMID 16797799</ref><ref>Rodriguez WJ, Schwartz RH, Thorne MM. Evaluation of diagnostic tests for influenza in a pediatric practice. Pediatr Infect Dis J. 2002 Mar;21(3):193-6. PMID 12005080</ref>
[[Image:Flu-virus2.jpg|right|thumb|350px|{{#ifexist:Template:Flu-virus2.jpg/credit|{{Flu-virus2.jpg/credit}}<br/>|}}An electron tomography of the influenza virus.]]
 
Rapid influenza diagnostic tests (RIDT)  using [[immunosorbent technique]] for influenza antigens have a sensitivity of about 50% and specificity of about 85%<ref name="pmid19779397">{{cite journal| author=Centers for Disease Control and Prevention (CDC)| title=Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection - Connecticut, 2009. | journal=MMWR Morb Mortal Wkly Rep | year= 2009 | volume= 58 | issue= 37 | pages= 1029-32 | pmid=19779397
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19779397 }}</ref>
 
The [[polymerase chain reaction]] is the most [[sensitivity and specificity|sensitive]] test and is as sensitive as viral culture.<ref name="pmid19281331" />
 
===Differential diagnosis===
===Differential diagnosis===
''Influenza-like illness'' is defined as "fever (temperature of 100°F [37.8°C] or greater) and a cough and/or a sore throat in the absence of a known cause other than influenza."<ref name="titleCDC">{{cite web |url=http://www.cdc.gov/flu/weekly/fluactivity.htm |title=CDC - Influenza (Flu) - Flu Activity|author=Centers for Disease Control and Prevention |accessdate=2007-11-19 |format= |work=|year=2007}}</ref> A study from [[Australia]] found that possible causes for influenza-like illness include respiratory syncytial virus, rhinovirus, [[human adenovirus|adenovirus]], parainfluenza  viruses, coronaviruses, and metapneumovirus.<ref name="pmid15227858">{{cite journal |author=Kelly H, Birch C |title=The causes and diagnosis of influenza-like illness |journal=Australian family physician |volume=33 |issue=5 |pages=305–9 |year=2004 |pmid=15227858 |doi=}}</ref>
''Influenza-like illness'' is defined as "fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat"<ref name="titleCDC">{{cite web |url=http://www.cdc.gov/flu/weekly/index.htm |title=Seasonal Influenza (Flu) |author=Centers for Disease Control and Prevention |accessdate=2012-11-11 |format= |work=|year=2012}}</ref> A study from [[Australia]] found that possible causes for influenza-like illness include respiratory syncytial virus, rhinovirus, [[human adenovirus|adenovirus]], parainfluenza  viruses, coronaviruses, and metapneumovirus.<ref name="pmid15227858">{{cite journal |author=Kelly H, Birch C |title=The causes and diagnosis of influenza-like illness |journal=Australian family physician |volume=33 |issue=5 |pages=305–9 |year=2004 |pmid=15227858 |doi=}}</ref>


Other diagnoses to consider are:
Other diagnoses to consider are:
Line 132: Line 171:


==Treatment==
==Treatment==
The two classes of anti-virals are neuraminidase inhibitors and M2 inhibitors ([[adamantane]] derivatives). Neuraminidase inhibitors are currently preferred for flu virus infections.
The two classes of [[antiviral agent]]s are neuraminidase inhibitors and M2 inhibitors ([[adamantane]] derivatives). Neuraminidase inhibitors are currently preferred for flu virus infections.


Different strains of influenza virus have differing degrees of resistance against these antivirals and it is impossible to predict what degree of resistance a future pandemic strain might have.<ref> {{cite journal | last = Webster | first = Robert G. | title = H5N1 Influenza — Continuing Evolution and Spread | url=http://content.nejm.org/cgi/content/full/355/21/2174 | journal = N Engl J Med | volume = 355 | issue = 21 | pages = 2174–77 | year = 2006 | id = PMID 16192481}}</ref>
Different strains of influenza virus have differing degrees of resistance against these antivirals and it is impossible to predict what degree of resistance a future pandemic strain might have.<ref> {{cite journal | last = Webster | first = Robert G. | title = H5N1 Influenza — Continuing Evolution and Spread | url=http://content.nejm.org/cgi/content/full/355/21/2174 | journal = N Engl J Med | volume = 355 | issue = 21 | pages = 2174–77 | year = 2006 | id = PMID 16192481}}</ref>
In the United States, the [[Centers for Disease Control and Prevention]] have issued recommendations for the use of [[antiviral agent]]s.<ref>Advisory Committee on Immunization Practices (2011) [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza]. Morbidity and Mortality Weekly Report</ref> The CDC recommends [[oseltamivir]] or [[zanamivir]].


===When to treat===
===When to treat===
Line 144: Line 185:


===Neuraminidase inhibitors===
===Neuraminidase inhibitors===
These drugs are often effective against both influenza A and B.<ref name="pmid10459804">{{cite journal | last = Stephenson | first = I | coauthors = Nicholson K | title = Chemotherapeutic control of influenza | url=http://jac.oxfordjournals.org/cgi/content/full/44/1/6 | journal = J Antimicrob Chemother | volume = 44 | issue = 1 | pages = 6–10 | year = 1999 | id = PMID 10459804}}</ref> Examples are [[oseltamivir]] (trade name Tamiflu) and [[zanamivir]] (trade name Relenza) are [[neuraminidase inhibitor]]s.<ref name= Neuraminidase_inhibitors>{{cite journal | last = Moscona | first = A | title = Neuraminidase inhibitors for influenza | url=http://content.nejm.org/cgi/content/full/353/13/1363 | journal = N Engl J Med | volume = 353 | issue = 13 | pages = 1363–73 | year = 2005 | id = PMID 16192481}}</ref>  The [[Cochrane Collaboration]] concluded that these drugs reduce symptoms and complications.<ref name="pmid16855962">{{cite journal | last = Jefferson | first = T | coauthors = Demicheli V, Di Pietrantonj C, Jones M, Rivetti D | title = Neuraminidase inhibitors for preventing and treating influenza in healthy adults | journal = Cochrane Database Syst Rev | volume = 3 | issue = | pages = CD001265 | year = | doi = 10.1002/14651858.CD001265.pub2 | id = PMID 16855962}}</ref>  Zanamivir may cause bronchospasm in patients with asthma.
These drugs are effective, but modestly so, against both influenza A and B.<ref name="pmid19995812">{{cite journal| author=Jefferson T, Jones M, Doshi P, Del Mar C| title=Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. | journal=BMJ | year= 2009 | volume= 339 | issue= | pages= b5106 | pmid=19995812
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19995812 | doi=10.1136/bmj.b5106 }}</ref><ref name="pmid20166059">{{cite journal| author=Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R| title=Neuraminidase inhibitors for preventing and treating influenza in healthy adults. | journal=Cochrane Database Syst Rev | year= 2010 | volume= 2 | issue= | pages= CD001265 | pmid=20166059
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20166059 | doi=10.1002/14651858.CD001265.pub3 }} </ref> Examples are [[oseltamivir]] (trade name Tamiflu) and [[zanamivir]] (trade name Relenza) are [[neuraminidase inhibitor]]s.<ref name= Neuraminidase_inhibitors>{{cite journal | last = Moscona | first = A | title = Neuraminidase inhibitors for influenza | url=http://content.nejm.org/cgi/content/full/353/13/1363 | journal = N Engl J Med | volume = 353 | issue = 13 | pages = 1363–73 | year = 2005 | id = PMID 16192481}}</ref>  The [[Cochrane Collaboration]] concluded that these drugs reduce symptoms and complications.<ref name="pmid16855962">{{cite journal | last = Jefferson | first = T | coauthors = Demicheli V, Di Pietrantonj C, Jones M, Rivetti D | title = Neuraminidase inhibitors for preventing and treating influenza in healthy adults | journal = Cochrane Database Syst Rev | volume = 3 | issue = | pages = CD001265 | year = | doi = 10.1002/14651858.CD001265.pub2 | id = PMID 16855962}}</ref>  Zanamivir, which must be delivered by inhalation, may cause bronchospasm in patients with asthma.
 
Oseltamivir may<ref name="pmid10697061">{{cite journal |author=Treanor JJ, Hayden FG, Vrooman PS, ''et al'' |title=Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group |journal=JAMA |volume=283 |issue=8 |pages=1016–24 |year=2000 |pmid=10697061 |doi=}}</ref> or may not<ref name="pmid19995812">{{cite journal| author=Jefferson T, Jones M, Doshi P, Del Mar C| title=Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. | journal=BMJ | year= 2009 | volume= 339 | issue=  | pages= b5106 | pmid=19995812
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19995812 | doi=10.1136/bmj.b5106 }}</ref> reduce the incidence of respiratory complications on one of 13 patients who take it ([[number needed to treat]] = 13). This trial only included patients up to 65 years old.
 
Neither of these drugs can be administered by injection. For the 2009 pandemic, the U.S. [[Food and Drug Administration]] issued an emergency authorization for the use of intravenous peramavir, which had been in [[New Drug Application|Phase III clinical trials]]. <ref name=FDA-EUA-par>{{citation
| url = http://cdc.gov/h1n1flu/eua/peramivir.htm
| title = Emergency Use Authorization of Peramivir IV
| publisher = [[Centers for Disease Control]]}}</ref>


===M2 inhibitors (adamantanes) ===
===M2 inhibitors (adamantanes) ===
These drugs are sometimes effective against influenza A if given early in the infection, but are always ineffective against influenza B. Examples include the [[antiviral drug]]s [[amantadine]] and [[rimantadine]] which block a viral ion channel and prevent the virus from infecting cells. <ref name="pmid10459804"/>
These drugs are sometimes effective against influenza A if given early in the infection, but are always ineffective against influenza B. Examples include the [[antiviral drug]]s [[amantadine]] and [[rimantadine]] which block a viral ion channel and prevent the virus from infecting cells.<ref name="pmid10459804">{{cite journal| author=Stephenson I, Nicholson KG| title=Chemotherapeutic control of influenza. | journal=J Antimicrob Chemother | year= 1999 | volume= 44 | issue= 1 | pages= 6-10 | pmid=10459804 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10459804  }} </ref>


==Prevention==
==Prevention==
===Barriers===
{{Image|N95.jpg|right|350px|N95 mask. This mask is '''''NOT''''' better than a regular surgical mask.}}
A regular surgical mask is adequate.<ref>{{Cite journal
| doi = 10.1001/jama.2009.1466
| pages = 2009.1466
| last = Loeb
| first = Mark
| coauthors = Nancy Dafoe, James Mahony, Michael John, Alicia Sarabia, Verne Glavin, Richard Webby, Marek Smieja, David J. D. Earn, Sylvia Chong, Ashley Webb, Stephen D. Walter
| title = Surgical Mask vs N95 Respirator for Preventing Influenza Among Health Care Workers: A Randomized Trial
| journal = JAMA
| accessdate = 2009-10-02
| date = 2009-10-01
| url = http://jama.ama-assn.org/cgi/content/abstract/2009.1466v1
}}</ref>
===Vaccination===
===Vaccination===
In the [[United States]], the [[Centers for Disease Control and Prevention]] has published recommendations on who should get the influenza vaccination.<ref name="titleCDC - Influenza (Flu) | Vaccination">{{cite web |url=http://www.cdc.gov/flu/professionals/vaccination/index.htm |title=CDC - Influenza (Flu): Vaccination |accessdate=2007-11-29 |author=Centers for Disease Control and Prevention |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> Protection from infection occurs by two weeks after vaccination and lasts one year.<ref name="titleCDC - Influenza (Flu) | Vaccination"/>
In the [[United States of America]], the [[Centers for Disease Control and Prevention]] has maintains recommendations on who should get the influenza vaccination.<ref name="titleCDC - Influenza (Flu) | Vaccination">{{cite web |url=http://www.cdc.gov/flu/professionals/vaccination/ |title=Seasonal Influenza Vaccination Resources for Health Professionals|accessdate=2014-12-16 |author=Centers for Disease Control and Prevention |authorlink= |coauthors= |date=2014|format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> Protection from infection occurs by two weeks after vaccination and lasts one year.<ref name="titleCDC - Influenza (Flu) | Vaccination"/>


===Neuraminidase inhibitors===
The quality of the research on vaccination my be reduced by [[conflict of interest]] according to the [[Cochrane Collaboration]].<ref name="pmid20614424">{{cite journal| author=Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E| title=Vaccines for preventing influenza in healthy adults. | journal=Cochrane Database Syst Rev | year= 2010 | volume= 7 | issue=  | pages= CD001269 | pmid=20614424 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20614424 | doi=10.1002/14651858.CD001269.pub4 }} </ref>
The [[Cochrane Collaboration]] has concluded that neuraminidase inhibitors can prevent symptomatic influenza.<ref name="pmid16855962"/> Zanamivir may cause bronchospasm in patients with asthma. In addition, oseltamivir may reduce the incidence of respiratory complications on one of 13 patients who take it ([[number needed to treat]] = 13).<ref name="pmid10697061">{{cite journal |author=Treanor JJ, Hayden FG, Vrooman PS, ''et al'' |title=Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group |journal=JAMA |volume=283 |issue=8 |pages=1016–24 |year=2000 |pmid=10697061 |doi=}}</ref> This trial only included patients up to 65 years old.
 
{| class="wikitable"
!
! colspan="4" style="text-align: center;" | Inactivated
! style="text-align: center;" | Live attenuated
(intranasal)
|-
!
! style="text-align: center;" | Mammalian cells
! style="text-align: center;" | Recombinant
! colspan="2" style="text-align: center;" | Embryonated chicken eggs
! style="text-align: center;" | Normal
|-
!
! style="text-align: center;" | Trivalent
! style="text-align: center;" | Trivalent
! style="text-align: center;" | Trivalent
! style="text-align: center;" | Quadrivalent
! style="text-align: center;" | Quadrivalent
|-
| High dose
| style="text-align: center;" |
| style="text-align: center;" |
| style="text-align: center;" | Fluzone high-dose.
[[Centers for Disease Control|CDC]] lists as an option for age > 65 years old
| style="text-align: center;" |
| style="text-align: center;" |
|-
| Standard dose
| style="text-align: center;" | Flucelvax†
| style="text-align: center;" | FluBlok†
| style="text-align: center;" | Needle-free jet‡
| style="text-align: center;" | [[Centers for Disease Control|CDC]] lists as an option for age < 65 years old
| style="text-align: center;" |
|-
| Low dose
| style="text-align: center;" |
| style="text-align: center;" |
| style="text-align: center;" | Fluzone intradermal‡
| style="text-align: center;" |
| style="text-align: center;" |
|-
| colspan="6" | †  For egg allergy<br/>‡ For needle phobia
|}
 
====Adverse effects====
Several randomized placebo-controlled trials assess adverse effects<ref name="pmid7666874">{{cite journal| author=Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M et al.| title=The effectiveness of vaccination against influenza in healthy, working adults. | journal=N Engl J Med | year= 1995 | volume= 333 | issue= 14 | pages= 889-93 | pmid=7666874 | doi=10.1056/NEJM199510053331401 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7666874  }} </ref> <ref name="pmid10411194">{{cite journal| author=Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB et al.| title=Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. | journal=JAMA | year= 1999 | volume= 282 | issue= 2 | pages= 137-44 | pmid=10411194 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10411194  }} </ref>, including patients who have lung disease<ref name="pmid11794219">{{cite journal| author=| title=The safety of inactivated influenza vaccine in adults and children with asthma. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 21 | pages= 1529-36 | pmid=11794219 | doi=10.1056/NEJMoa011961 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11794219  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12123261 Review in: Evid Based Nurs. 2002 Jul;5(3):77]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12093217 Review in: ACP J Club. 2002 Jul-Aug;137(1):18] </ref> or are elderly<ref name="pmid2200894">{{cite journal| author=Margolis KL, Nichol KL, Poland GA, Pluhar RE| title=Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. | journal=JAMA | year= 1990 | volume= 264 | issue= 9 | pages= 1139-41 | pmid=2200894 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2200894  }} </ref> <ref name="pmid8241913">{{cite journal| author=Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA| title=Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. | journal=BMJ | year= 1993 | volume= 307 | issue= 6910 | pages= 988-90 | pmid=8241913 | doi= | pmc=PMC1679213 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8241913  }} </ref>.
 
Among health adults, vaccination may be associated with arm pain<ref name="pmid7666874">{{cite journal| author=Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M et al.| title=The effectiveness of vaccination against influenza in healthy, working adults. | journal=N Engl J Med | year= 1995 | volume= 333 | issue= 14 | pages= 889-93 | pmid=7666874 | doi=10.1056/NEJM199510053331401 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7666874  }} </ref> and "runny nose or sore throat during the first 7 days after vaccination"<ref name="pmid10411194">{{cite journal| author=Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB et al.| title=Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. | journal=JAMA | year= 1999 | volume= 282 | issue= 2 | pages= 137-44 | pmid=10411194 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10411194  }} </ref>.
 
Among patients with asthma, vaccination was associated with body aches.<ref name="pmid11794219">{{cite journal| author=| title=The safety of inactivated influenza vaccine in adults and children with asthma. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 21 | pages= 1529-36 | pmid=11794219 | doi=10.1056/NEJMoa011961 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11794219  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12123261 Review in: Evid Based Nurs. 2002 Jul;5(3):77]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12093217 Review in: ACP J Club. 2002 Jul-Aug;137(1):18] </ref>
 
Among elderly patients, the influenza vaccine may increase arm pain.<ref name="pmid2200894">{{cite journal| author=Margolis KL, Nichol KL, Poland GA, Pluhar RE| title=Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. | journal=JAMA | year= 1990 | volume= 264 | issue= 9 | pages= 1139-41 | pmid=2200894 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2200894  }} </ref> <ref name="pmid8241913">{{cite journal| author=Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA| title=Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. | journal=BMJ | year= 1993 | volume= 307 | issue= 6910 | pages= 988-90 | pmid=8241913 | doi= | pmc=PMC1679213 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8241913  }} </ref>
 
===Chemoprevention===
[[Chemoprevention]] (chemoprophylaxis) with neuraminidase inhibitors can prevent symptomatic influenza according to a [[meta-analysis]] by the [[Cochrane Collaboration]].<ref name="pmid16855962" />Zanamivir may cause bronchospasm in patients with asthma. Extended-duration (>4 weeks) chemoprevention may be effective as well.<ref name="pmid19652173">{{cite journal| author=Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK| title=Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. | journal=Ann Intern Med | year= 2009 | volume=  | issue=  | pages=  | pmid=19652173
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19652173 }}</ref>


==Pandemics and notable outbreaks==
==Pandemics and notable outbreaks==
Line 160: Line 282:
A pandemic of Spanish Influenza, involving a highly pathogenic mutation of serotype H1N1, swept across the world in the wake of the Great War (1918-20). More people are believed to have died of the flu in the year after the war then in the Great War itself. Estimates vary but it is estimated that one third of the world's population were infected and  up to 50 million people perished in this pandemic (it is possibly that fatalities world wide were as high as 100 million).<ref>http://www.cdc.gov/ncidod/EID/vol12no01/05-0979.htm</ref> Some comparisons are drawn between Spanish Flu and the Black Death (Bubonic Plague) of 1347 to 1351. Estimates are that the flu killed more people in one year than plague did in four.
A pandemic of Spanish Influenza, involving a highly pathogenic mutation of serotype H1N1, swept across the world in the wake of the Great War (1918-20). More people are believed to have died of the flu in the year after the war then in the Great War itself. Estimates vary but it is estimated that one third of the world's population were infected and  up to 50 million people perished in this pandemic (it is possibly that fatalities world wide were as high as 100 million).<ref>http://www.cdc.gov/ncidod/EID/vol12no01/05-0979.htm</ref> Some comparisons are drawn between Spanish Flu and the Black Death (Bubonic Plague) of 1347 to 1351. Estimates are that the flu killed more people in one year than plague did in four.


In the [[United States]], the epidemic led to closing of schools and banning of public meetings in order to successfully reduce mortality.<ref name="pmid17684187">{{cite journal |author=Markel H, Lipman HB, Navarro JA, ''et al'' |title=Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic |journal=JAMA |volume=298 |issue=6 |pages=644–54 |year=2007 |pmid=17684187 |doi=10.1001/jama.298.6.644}}</ref>
In the [[United States of America]], the epidemic led to closing of schools and banning of public meetings in order to successfully reduce mortality.<ref name="pmid17684187">{{cite journal |author=Markel H, Lipman HB, Navarro JA, ''et al'' |title=Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic |journal=JAMA |volume=298 |issue=6 |pages=644–54 |year=2007 |pmid=17684187 |doi=10.1001/jama.298.6.644}}</ref>
===Asian influenza pandemic of 1957 - 1963===
===Asian influenza pandemic of 1957 - 1963===
A/H2N2 virus was responsible for this outbreak
A/H2N2 virus was responsible for this outbreak
Line 166: Line 288:
This was caused by serotype A/H3N2.  
This was caused by serotype A/H3N2.  
==References==
==References==
{{reflist|2}}
{{reflist|2}}[[Category:Suggestion Bot Tag]]

Latest revision as of 06:01, 1 September 2024

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Influenza&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Influenza, commonly called “the ‘Flu”, is described as "an acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the nasal mucosa; the pharynx; and conjunctiva, and by headache and severe, often generalized, myalgia".[1] It is contagious (easily passed from one person to another) and is caused by viruses of the Orthomyxoviridae family.

Classification

There are three types of influenza viruses:[2]

Hosts

Influenza in humans

In April, 2009, the 2009 H1N1 influenza virus was first isolated and is a novel H1N1 strain that was initially untypeable. The 2009 novel H1N1 influenza virus contains genes normally found in North American swine as well as two genes found in European and Asian swine and has been called a triple-reassortant of genes.[3][4]

In the 2007-2008 season, the most common strains of influenza in the United States were:[5]

In the 1999-2000 season, the most common strains of influenza in the United States were:[6]

Equine Influenza

This is a species-specific strain that infects horses, ponies, donkeys and mules. Humans do not catch this disease but are carriers of it. It is airborne and highly contagious. Equine influenza generally does not kill its victims, and affected horses display similar symptoms to those of humans.

In 2007, a horse flu epidemic began in New South Wales, Australia. The outbreak is believed to have begun as a result of infractions of proper quarantine procedure and is expected to cost millions of dollars in lost revenue. As of September, 2007, it had spread to the Victorian border, causing the cancellation of events at the Melbourne Show, and the possibility that the Spring Carnival, including the running of the Melbourne Cup horse race, would be canceled.

Avian flu

Avian flu, also known as Bird flu or H5N1, has led to recent outbreaks.[7][8]

Epidemiology

Seasonal influenza activity in the United States of America over four years. During the off season, the prevalence is < 2%. During the height of season, the prevalence may be 20-35%.[9]

Current influenza activity can be monitored online:

The prevalence of influenza among people who have an "influenza-like illness" varies strongly with the seasons of the year. In the United States of America, the Centers for Disease Control and Prevention (CDC) maintains public statistics at http://www.cdc.gov/flu/weekly/fluactivity.htm.

  • During the off season, the prevalence is < 2%[9]
  • During the height of season, the prevalence may be 20-35%.[9]
  • During local outbreaks, the prevalence may be 50-80% according to studies.[11][12] Unfortunately, the CDC does not report sufficient details to determine where local outbreaks are occurring.

In addition to seasonal variations, there have been several worldwide influenza epidemics, resulting in millions of deaths.

Diagnosis

History and physical examination

Since anti-viral drugs are effective in treating influenza if given early (see treatment section, below), it can be important to identify cases early. A systematic review by the Rational Clinical Examination concluded that the best findings for excluding the diagnosis of influenza are:[13]

Most sensitive individual findings for diagnosing influenza[13]
Finding: Sensitivity Specificity
Fever† 86%† 25%
Cough† 98%† 23%
Sore throat ~80%† ~30%
Nasal congestion† 70–90%† 20–40%
Absence of vaccination 83-97% 14-19%[14][15]
Note:
† All three findings, especially fever, were less sensitive in patients over 60 years of age.[13]

Using the symptoms listed above, the combinations of findings below can improve diagnostic accuracy.[16] Unfortunately, even combinations of findings are imperfect. Studies of combining symptoms have included use of recursive partitioning; however, this study combined two cohorts with different prevalences of influenza.[17] However, Bayes Theorem can combine pretest probability with clinical findings to adequately diagnose or exclude influenza in some patients. The pretest probability has a strong seasonal variation; the current prevalence of influenza among patients in the United States receiving sentinel testing is available at the CDC.[18] Using the CDC data, the following table shows how the likelihood of influenza varies with prevalence:

Combinations of findings for diagnosing influenza[19][13]
Combinations of findings Sensitivity Specificity Projected during local outbreaks
(prevalence approx 66%[20][12]) 		Projected during influenza season
(prevalence=25%)		 Projected in off-season
(prevalence=2%)
PPV NPV PPV NPV PPV NPV
Fever and cough 64%
61%[19]		 67%
80%[19]		 79%
86%[19]		 49%
49%[19]		 39%
50%[19]		 15%
14%[19]		 4%
6%[19]		 1%
1%[19]
Fever and cough and sore throat 56 71 79 45 39 17 4 2
Fever and cough and nasal congestion 59 74 81 48 43 16 4 1
Fever and cough and acute onset[19] 41 93 92 55 66 18 11 1

Laboratory tests

An electron tomography of the influenza virus.

Available tests are listed at the CDC website.

Clinical practice guidelines address diagnosis.[21]

Rapid tests using for influenza antigens include immunofluorescence assays, immunoenzyme technique, and polymerase chain reaction testing. The sensitivity of these tests range from 63% to 95%.[22][23]

Rapid influenza diagnostic tests (RIDT) using immunosorbent technique for influenza antigens have a sensitivity of about 50% and specificity of about 85%[24]

The polymerase chain reaction is the most sensitive test and is as sensitive as viral culture.[21]

Differential diagnosis

Influenza-like illness is defined as "fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat"[25] A study from Australia found that possible causes for influenza-like illness include respiratory syncytial virus, rhinovirus, adenovirus, parainfluenza viruses, coronaviruses, and metapneumovirus.[26]

Other diagnoses to consider are:

Treatment

The two classes of antiviral agents are neuraminidase inhibitors and M2 inhibitors (adamantane derivatives). Neuraminidase inhibitors are currently preferred for flu virus infections.

Different strains of influenza virus have differing degrees of resistance against these antivirals and it is impossible to predict what degree of resistance a future pandemic strain might have.[27]

In the United States, the Centers for Disease Control and Prevention have issued recommendations for the use of antiviral agents.[28] The CDC recommends oseltamivir or zanamivir.

When to treat

According to two decision analysis studies of adults, treatment may be justified in the following settings:

  • Elderly patients if the probability of influenza is over 14%[12]
  • Adults if the probability of influenza is over 30%[11].

During local outbreaks of influenza, the prevalence will be over 50-80%[20][12] and thus patients with any of the above combinations of symptoms may be treated with neuramidase inhibitors without testing. In the absence of a local outbreak, treatment may be justified in the elderly during the influenza season as long as the prevalence is over 15%.[12]

Neuraminidase inhibitors

These drugs are effective, but modestly so, against both influenza A and B.[29][30] Examples are oseltamivir (trade name Tamiflu) and zanamivir (trade name Relenza) are neuraminidase inhibitors.[31] The Cochrane Collaboration concluded that these drugs reduce symptoms and complications.[32] Zanamivir, which must be delivered by inhalation, may cause bronchospasm in patients with asthma.

Oseltamivir may[33] or may not[29] reduce the incidence of respiratory complications on one of 13 patients who take it (number needed to treat = 13). This trial only included patients up to 65 years old.

Neither of these drugs can be administered by injection. For the 2009 pandemic, the U.S. Food and Drug Administration issued an emergency authorization for the use of intravenous peramavir, which had been in Phase III clinical trials. [34]

M2 inhibitors (adamantanes)

These drugs are sometimes effective against influenza A if given early in the infection, but are always ineffective against influenza B. Examples include the antiviral drugs amantadine and rimantadine which block a viral ion channel and prevent the virus from infecting cells.[35]

Prevention

Barriers

N95 mask. This mask is NOT better than a regular surgical mask.

A regular surgical mask is adequate.[36]

Vaccination

In the United States of America, the Centers for Disease Control and Prevention has maintains recommendations on who should get the influenza vaccination.[37] Protection from infection occurs by two weeks after vaccination and lasts one year.[37]

The quality of the research on vaccination my be reduced by conflict of interest according to the Cochrane Collaboration.[38]

Inactivated Live attenuated

(intranasal)

Mammalian cells Recombinant Embryonated chicken eggs Normal
Trivalent Trivalent Trivalent Quadrivalent Quadrivalent
High dose Fluzone high-dose.

CDC lists as an option for age > 65 years old

Standard dose Flucelvax† FluBlok† Needle-free jet‡ CDC lists as an option for age < 65 years old
Low dose Fluzone intradermal‡
† For egg allergy
‡ For needle phobia

Adverse effects

Several randomized placebo-controlled trials assess adverse effects[39] [40], including patients who have lung disease[41] or are elderly[42] [43].

Among health adults, vaccination may be associated with arm pain[39] and "runny nose or sore throat during the first 7 days after vaccination"[40].

Among patients with asthma, vaccination was associated with body aches.[41]

Among elderly patients, the influenza vaccine may increase arm pain.[42] [43]

Chemoprevention

Chemoprevention (chemoprophylaxis) with neuraminidase inhibitors can prevent symptomatic influenza according to a meta-analysis by the Cochrane Collaboration.[32]Zanamivir may cause bronchospasm in patients with asthma. Extended-duration (>4 weeks) chemoprevention may be effective as well.[44]

Pandemics and notable outbreaks

Spanish influenza pandemic of 1918-1920

A pandemic of Spanish Influenza, involving a highly pathogenic mutation of serotype H1N1, swept across the world in the wake of the Great War (1918-20). More people are believed to have died of the flu in the year after the war then in the Great War itself. Estimates vary but it is estimated that one third of the world's population were infected and up to 50 million people perished in this pandemic (it is possibly that fatalities world wide were as high as 100 million).[45] Some comparisons are drawn between Spanish Flu and the Black Death (Bubonic Plague) of 1347 to 1351. Estimates are that the flu killed more people in one year than plague did in four.

In the United States of America, the epidemic led to closing of schools and banning of public meetings in order to successfully reduce mortality.[46]

Asian influenza pandemic of 1957 - 1963

A/H2N2 virus was responsible for this outbreak

Hong Kong pandemic 1968-1970

This was caused by serotype A/H3N2.

References

  1. ↑ National Library of Medicine. "Influenza". [e]
  2. ↑ 2.0 2.1 Anonymous (2005)Influenza Viruses, Centers for Disease Control and Prevention
  3. ↑ Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S et al. (2009). "Emergence of a novel swine-origin influenza A (H1N1) virus in humans.". N Engl J Med 360 (25): 2605-15. DOI:10.1056/NEJMoa0903810. PMID 19423869. Research Blogging.
  4. ↑ Swine Flu & You
  5. ↑ 2007-08 U.S. INFLUENZA SEASON SUMMARY, Centers for Disease Control and Prevention
  6. ↑ 1999-2000 INFLUENZA SEASON SUMMARY, Centers for Disease Control and Prevention
  7. ↑ Oner AF, Bay A, Arslan S, et al (2006). "Avian influenza A (H5N1) infection in eastern Turkey in 2006". N. Engl. J. Med. 355 (21): 2179–85. DOI:10.1056/NEJMoa060601. PMID 17124015. Research Blogging.
  8. ↑ Kandun IN, Wibisono H, Sedyaningsih ER, et al (2006). "Three Indonesian clusters of H5N1 virus infection in 2005". N. Engl. J. Med. 355 (21): 2186–94. DOI:10.1056/NEJMoa060930. PMID 17124016. Research Blogging.
  9. ↑ 9.0 9.1 9.2 Centers for Disease Control and Prevention. Flu Activity. Retrieved on 2007-11-29.
  10. ↑ Helft M (Nov 11, 2008). Google Uses Web Searches to Track Flu’s Spread - NYTimes.com. New York Times Company. Retrieved on 2008-11-11.
  11. ↑ 11.0 11.1 Smith K, Roberts M (2002). "Cost-effectiveness of newer treatment strategies for influenza.". Am J Med 113 (4): 300-7. DOI:10.1016/S0002-9343(02)01222-6. PMID 12361816. Research Blogging.
  12. ↑ 12.0 12.1 12.2 12.3 12.4 Rothberg M, Bellantonio S, Rose D (2003). "Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.". Ann Intern Med 139 (5 Pt 1): 321-9. PMID 12965940.
  13. ↑ 13.0 13.1 13.2 13.3 Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP (2005). "Does this patient have influenza?". JAMA 293 (8): 987-97. DOI:10.1001/jama.293.8.987. PMID 15728170. Research Blogging. Review in: Evid Based Nurs. 2005 Oct;8(4):121
  14. ↑ Hulson TD, Mold JW, Scheid D, et al (December 2001). "Diagnosing influenza: the value of clinical clues and laboratory tests". J Fam Pract 50 (12): 1051–6. PMID 11742606. [e]
  15. ↑ van Elden LJ, van Essen GA, Boucher CA, et al (August 2001). "Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice". Br J Gen Pract 51 (469): 630–4. PMID 11510391. PMC 1314072. [e]
  16. ↑ Monto A, Gravenstein S, Elliott M, Colopy M, Schweinle J (2000). "Clinical signs and symptoms predicting influenza infection.". Arch Intern Med 160 (21): 3243–7. PMID 11088084.
  17. ↑ Afonso AM, Ebell MH, Gonzales R, Stein J, Genton B, Senn N (2012). "The use of classification and regression trees to predict the likelihood of seasonal influenza.". Fam Pract. DOI:10.1093/fampra/cms020. PMID 22427440. Research Blogging.
  18. ↑ Centers for Disease Control and Prevention. Weekly Report: Influenza Summary Update. Accessed January 1, 2007.
  19. ↑ 19.0 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 Ebell MH, Afonso AM, Gonzales R, Stein J, Genton B, Senn N (2012). "Development and validation of a clinical decision rule for the diagnosis of influenza.". J Am Board Fam Med 25 (1): 55-62. DOI:10.3122/jabfm.2012.01.110161. PMID 22218625. Research Blogging.
  20. ↑ 20.0 20.1 Smith K, Roberts M (2002). "Cost-effectiveness of newer treatment strategies for influenza.". Am J Med 113 (4): 300-7. DOI:10.1016/S0002-9343(02)01222-6. PMID 12361816. Research Blogging.
  21. ↑ 21.0 21.1 Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG et al. (2009). "Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.". Clin Infect Dis 48 (8): 1003-32. DOI:10.1086/598513. PMID 19281331. Research Blogging.
  22. ↑ Beyer WE. Heterogeneity of case definitions used in vaccine effectiveness studies--and its impact on meta-analysis. Vaccine. 2006 Nov 10;24(44-46):6602-4. Epub 2006 Jun 8. PMID 16797799
  23. ↑ Rodriguez WJ, Schwartz RH, Thorne MM. Evaluation of diagnostic tests for influenza in a pediatric practice. Pediatr Infect Dis J. 2002 Mar;21(3):193-6. PMID 12005080
  24. ↑ Centers for Disease Control and Prevention (CDC) (2009). "Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection - Connecticut, 2009.". MMWR Morb Mortal Wkly Rep 58 (37): 1029-32. PMID 19779397.
  25. ↑ Centers for Disease Control and Prevention (2012). Seasonal Influenza (Flu). Retrieved on 2012-11-11.
  26. ↑ Kelly H, Birch C (2004). "The causes and diagnosis of influenza-like illness". Australian family physician 33 (5): 305–9. PMID 15227858. [e]
  27. ↑ Webster, Robert G. (2006). "H5N1 Influenza — Continuing Evolution and Spread". N Engl J Med 355 (21): 2174–77. PMID 16192481.
  28. ↑ Advisory Committee on Immunization Practices (2011) Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Morbidity and Mortality Weekly Report
  29. ↑ 29.0 29.1 Jefferson T, Jones M, Doshi P, Del Mar C (2009). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.". BMJ 339: b5106. DOI:10.1136/bmj.b5106. PMID 19995812. Research Blogging.
  30. ↑ Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R (2010). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults.". Cochrane Database Syst Rev 2: CD001265. DOI:10.1002/14651858.CD001265.pub3. PMID 20166059. Research Blogging.
  31. ↑ Moscona, A (2005). "Neuraminidase inhibitors for influenza". N Engl J Med 353 (13): 1363–73. PMID 16192481.
  32. ↑ 32.0 32.1 Jefferson, T; Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. "Neuraminidase inhibitors for preventing and treating influenza in healthy adults". Cochrane Database Syst Rev 3: CD001265. DOI:10.1002/14651858.CD001265.pub2. PMID 16855962. Research Blogging.
  33. ↑ Treanor JJ, Hayden FG, Vrooman PS, et al (2000). "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group". JAMA 283 (8): 1016–24. PMID 10697061. [e]
  34. ↑ Emergency Use Authorization of Peramivir IV, Centers for Disease Control
  35. ↑ Stephenson I, Nicholson KG (1999). "Chemotherapeutic control of influenza.". J Antimicrob Chemother 44 (1): 6-10. PMID 10459804. [e]
  36. ↑ Loeb, Mark; Nancy Dafoe, James Mahony, Michael John, Alicia Sarabia, Verne Glavin, Richard Webby, Marek Smieja, David J. D. Earn, Sylvia Chong, Ashley Webb, Stephen D. Walter (2009-10-01). "Surgical Mask vs N95 Respirator for Preventing Influenza Among Health Care Workers: A Randomized Trial". JAMA: 2009.1466. DOI:10.1001/jama.2009.1466. Retrieved on 2009-10-02. Research Blogging.
  37. ↑ 37.0 37.1 Centers for Disease Control and Prevention (2014). Seasonal Influenza Vaccination Resources for Health Professionals. Retrieved on 2014-12-16.
  38. ↑ Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E (2010). "Vaccines for preventing influenza in healthy adults.". Cochrane Database Syst Rev 7: CD001269. DOI:10.1002/14651858.CD001269.pub4. PMID 20614424. Research Blogging.
  39. ↑ 39.0 39.1 Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M et al. (1995). "The effectiveness of vaccination against influenza in healthy, working adults.". N Engl J Med 333 (14): 889-93. DOI:10.1056/NEJM199510053331401. PMID 7666874. Research Blogging.
  40. ↑ 40.0 40.1 Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB et al. (1999). "Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.". JAMA 282 (2): 137-44. PMID 10411194. [e]
  41. ↑ 41.0 41.1 (2001) "The safety of inactivated influenza vaccine in adults and children with asthma.". N Engl J Med 345 (21): 1529-36. DOI:10.1056/NEJMoa011961. PMID 11794219. Research Blogging. Review in: Evid Based Nurs. 2002 Jul;5(3):77 Review in: ACP J Club. 2002 Jul-Aug;137(1):18
  42. ↑ 42.0 42.1 Margolis KL, Nichol KL, Poland GA, Pluhar RE (1990). "Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial.". JAMA 264 (9): 1139-41. PMID 2200894. [e]
  43. ↑ 43.0 43.1 Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA (1993). "Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial.". BMJ 307 (6910): 988-90. PMID 8241913. PMC PMC1679213. [e]
  44. ↑ Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK (2009). "Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza.". Ann Intern Med. PMID 19652173.
  45. ↑ http://www.cdc.gov/ncidod/EID/vol12no01/05-0979.htm
  46. ↑ Markel H, Lipman HB, Navarro JA, et al (2007). "Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic". JAMA 298 (6): 644–54. DOI:10.1001/jama.298.6.644. PMID 17684187. Research Blogging.
Retrieved from "https://citizendium.org/wiki/index.php?title=Influenza&oldid=975932"